Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 21 04:00PM ET
6.58
Dollar change
-0.05
Percentage change
-0.75
%
Index- P/E- EPS (ttm)-15.15 Insider Own13.32% Shs Outstand2.76M Perf Week-4.15%
Market Cap18.56M Forward P/E- EPS next Y-7.57 Insider Trans-2.59% Shs Float2.44M Perf Month3.95%
Income-39.55M PEG- EPS next Q-4.41 Inst Own21.90% Short Float0.36% Perf Quarter-7.84%
Sales0.00M P/S- EPS this Y16.48% Inst Trans-6.09% Short Ratio0.56 Perf Half Y20.73%
Book/sh2.37 P/B2.78 EPS next Y47.76% ROA-63.15% Short Interest0.01M Perf Year-60.34%
Cash/sh17.19 P/C0.38 EPS next 5Y40.90% ROE-262.61% 52W Range5.10 - 18.20 Perf YTD-6.00%
Dividend Est.- P/FCF- EPS past 5Y32.60% ROI-107.22% 52W High-63.85% Beta-1.97
Dividend TTM- Quick Ratio4.22 Sales past 5Y-16.79% Gross Margin97.38% 52W Low29.02% ATR (14)0.33
Dividend Ex-Date- Current Ratio4.22 EPS Y/Y TTM56.06% Oper. Margin0.00% RSI (14)41.80 Volatility3.34% 5.07%
Employees43 Debt/Eq5.49 Sales Y/Y TTM-100.00% Profit Margin- Recom1.00 Target Price16.50
Option/ShortNo / Yes LT Debt/Eq4.54 EPS Q/Q39.92% Payout- Rel Volume0.34 Prev Close6.63
Sales Surprise- EPS Surprise-45.33% Sales Q/Q- EarningsMay 14 AMC Avg Volume15.77K Price6.58
SMA20-2.22% SMA50-8.63% SMA200-19.58% Trades Volume5,318 Change-0.75%
Date Action Analyst Rating Change Price Target Change
Mar-30-22Downgrade JP Morgan Neutral → Underweight
Aug-06-21Downgrade JP Morgan Overweight → Neutral
Sep-14-20Downgrade Jefferies Buy → Hold $10
Jul-23-20Initiated Northland Capital Outperform
Jun-01-20Resumed Oppenheimer Outperform $21
May-27-20Reiterated H.C. Wainwright Buy $14 → $17
Mar-09-20Upgrade BofA/Merrill Neutral → Buy
Dec-17-19Downgrade BofA/Merrill Buy → Neutral $9 → $6
Mar-14-19Initiated Jefferies Buy $15
May-21-24 01:13PM
11:17AM
May-14-24 10:54PM
04:05PM
Apr-02-24 07:53AM
08:00AM Loading…
Mar-29-24 08:00AM
Feb-26-24 08:00AM
Feb-06-24 08:00AM
Jan-19-24 04:01PM
Nov-13-23 08:00AM
Sep-20-23 04:01PM
Sep-05-23 08:00AM
Aug-15-23 10:20AM
Aug-04-23 08:11AM
08:00AM
04:01PM Loading…
Aug-02-23 04:01PM
08:00AM
Jul-19-23 04:01PM
Jun-23-23 04:01PM
Jun-02-23 08:00AM
May-11-23 12:20PM
May-09-23 08:07AM
08:00AM
Apr-28-23 08:00AM
Apr-14-23 12:49PM
Apr-13-23 11:22AM
11:10AM
Apr-12-23 08:00AM
Apr-05-23 05:50PM
Apr-04-23 01:32PM
01:16PM Loading…
01:16PM
Mar-30-23 05:50PM
Mar-29-23 08:00AM
Mar-28-23 11:04AM
Mar-27-23 08:00AM
Mar-24-23 09:55AM
Mar-23-23 11:09AM
Mar-22-23 09:30AM
07:37AM
Mar-20-23 12:04PM
09:30AM
Mar-17-23 02:54PM
Mar-09-23 09:30AM
Mar-08-23 04:01PM
09:55AM
Mar-06-23 12:33PM
Mar-03-23 03:02PM
08:00AM
Mar-02-23 09:30AM
Feb-22-23 05:50PM
Feb-14-23 05:45PM
Feb-08-23 05:45PM
Feb-01-23 04:25PM
Jan-19-23 09:30AM
Jan-17-23 10:00AM
Dec-30-22 12:02PM
02:59AM
Dec-29-22 09:55AM
Dec-28-22 11:13AM
09:44AM
06:48AM
Dec-27-22 04:01PM
Dec-20-22 10:03AM
09:06AM
Dec-07-22 09:55AM
Dec-06-22 01:22PM
Nov-28-22 04:02PM
04:01PM
Nov-10-22 06:26AM
Nov-08-22 08:00AM
Nov-01-22 07:30AM
Oct-20-22 07:30AM
Sep-06-22 08:00AM
Aug-19-22 04:01PM
Aug-18-22 04:01PM
Aug-11-22 09:41AM
08:15AM
07:00AM
Aug-09-22 09:35AM
Aug-08-22 09:00AM
Aug-04-22 04:01PM
Jul-22-22 04:01PM
Jul-11-22 08:00AM
Jul-06-22 12:00PM
Jun-17-22 04:01PM
Jun-02-22 08:00AM
May-26-22 11:03AM
May-23-22 06:29AM
12:01AM
May-16-22 08:15AM
07:00AM
May-12-22 07:15AM
May-11-22 08:15AM
May-10-22 09:55AM
May-09-22 08:00AM
May-03-22 08:00AM
May-02-22 01:10PM
May-01-22 09:00AM
Apr-27-22 03:03PM
Apr-04-22 04:01PM
KALA BIO, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Iwicki Mark TCHIEF EXECUTIVE OFFICERJan 04 '24Sale6.734,53930,547286,315Jan 05 04:04 PM
Brazzell Romulus KSEE REMARKSJan 04 '24Sale6.741,61710,89991,473Jan 05 04:05 PM
Kharabi DariusCHIEF BUSINESS OFFICERJan 04 '24Sale6.731,3859,32165,117Jan 05 04:06 PM
Reumuth MaryCHIEF FINANCIAL OFFICERJan 04 '24Sale6.741,2278,27066,136Jan 05 04:04 PM
Trachtenberg EricSEE REMARKSJan 04 '24Sale6.741,2278,27068,066Jan 05 04:07 PM